Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results of the Open-label Extension (OLE) Trial (GWPCARE5)

被引：0
|
作者：
Thiele, E.
Marsh, E.
Halford, J.
Mazurkiewicz-Beldzinska, M.
Gunning, B.
Checketts, D.
Roberts, C.
机构：
来源：
ANNALS OF NEUROLOGY | 2018年 / 84卷
关键词：
Epilepsy; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
32
引用
收藏
页码：S336 / S336
页数：1
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results from Open-label Extension Trial (GWPCARE5)
    Halford, Jonathan
    Marsh, Eric
    Mazurkiewicz-Beldzinska, Maria
    Gunning, Boudewjin
    Checketts, Daniel
    Roberts, Claire
    Thiele, Elizabeth
    [J]. NEUROLOGY, 2018, 90
  • [2] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome (LGS) in an Open-Label Extension (OLE) Trial (GWPCARE5)
    Perry, M.
    Patel, A.
    Gil-Nagel, A.
    Chin, R.
    Mitchell, W.
    Weinstock, A.
    VanLandingham, K.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S76 - S77
  • [3] Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5)
    Patel, Anup
    Chin, Richard
    Mitchell, Wendy
    Perry, Scott
    Weinstock, Arie
    Checketts, Daniel
    Dunayevich, Eduardo
    [J]. NEUROLOGY, 2020, 94 (15)
  • [4] Long-Term Safety And Efficacy Of Add-on Cannabidiol (CBD) Treatment in Patients With Lennox-Gastaut Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Chin, R.
    Patel, A.
    Gil-Nagel, A.
    Mitchell, W.
    Perry, M. S.
    Weinstock, A.
    Whyte, L.
    VanLandingham, K.
    [J]. EPILEPSIA, 2019, 60 : 63 - 64
  • [5] Maintained Safety and Efficacy of Cannabidiol in a Long-Term Open-Label Trial in Patients with Lennox-Gastaut Syndrome (GWPCARE5)
    Marsh, E.
    Mazurkiewicz-Beldzinska, M.
    Halford, J.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    Thiele, E.
    [J]. EPILEPSIA, 2018, 59 : S9 - S9
  • [6] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5)
    Patel, Anup
    Gil-Nagel, Antonio
    Chin, Richard
    Mitchell, Wendy
    Perry, M. Scott
    Weinstock, Arie
    Roberts, Claire
    Whyte, Lauren
    VanLandingham, Kevan
    [J]. NEUROLOGY, 2019, 92 (15)
  • [7] Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)
    Laux, L.
    Devinsky, O.
    Miller, I
    Nabbout, R.
    Zolnowska, M.
    Wright, S.
    Roberts, C.
    [J]. ANNALS OF NEUROLOGY, 2018, 84 : S344 - S344
  • [8] Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)
    Miller, Ian
    Devinsky, Orrin
    Nabbout, Rima
    Laux, Linda
    Zolnowska, Marta
    Wright, Stephen
    Roberts, Claire
    [J]. NEUROLOGY, 2018, 90
  • [9] Long-term safety and efficacy of Cannabidiol (CBD) treatment in Lennox Gastaut syndrome: results overall and for patients completing 1-3 years of an open-label extension (GWPCARE5)
    Chin, R.
    Gil-Nagel, A.
    Mitchell, W.
    Patel, A. D.
    Perry, M. S.
    Weinstock, A.
    Checketts, D.
    Dunayevich, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 24 - 24
  • [10] Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
    Patel, Anup D.
    Mazurkiewicz-Beldzinska, Maria
    Chin, Richard F.
    Gil-Nagel, Antonio
    Gunning, Boudewijn
    Halford, Jonathan J.
    Mitchell, Wendy
    Scott Perry, Michael
    Thiele, Elizabeth A.
    Weinstock, Arie
    Dunayevich, Eduardo
    Checketts, Daniel
    Devinsky, Orrin
    [J]. EPILEPSIA, 2021, 62 (09) : 2228 - 2239
12345